AbbVie (ABBV) Change in Inventory (2012 - 2026)
AbbVie (ABBV) posted quarterly Change in Inventory of $184.0 million for Q1 2026, up 18.71% year-over-year from $155.0 million in Q1 2025, and up 636.0% quarter-over-quarter from $25.0 million in Q4 2025.
AbbVie (ABBV) Change in Inventory (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Change in Inventory for 15 consecutive years, with $184.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Inventory rose 18.71% year-over-year to $184.0 million; the TTM figure through Mar 2026 stood at $263.0 million (down 34.09% YoY), while the FY2025 annual figure was $234.0 million, down 26.65% from the prior year.
- Change in Inventory rose to $184.0 million in Q1 2026 per ABBV's latest filing, from $25.0 million in the prior quarter.
- Across five years, Change in Inventory topped out at $385.0 million in Q1 2022 and bottomed at -$96.0 million in Q4 2023.
- Historically, Change in Inventory has averaged $108.2 million across 5 years, with a median of $75.0 million in 2024.
- Annual changes were most pronounced in 2023 — Change in Inventory slumped 156.47% — and 2024, when it surged 233.33%.
- AbbVie's Change in Inventory stood at $170.0 million in 2022, then slumped by 156.47% to -$96.0 million in 2023, then soared by 233.33% to $128.0 million in 2024, then sank by 80.47% to $25.0 million in 2025, then soared by 636.0% to $184.0 million in 2026.
- Business Quant data shows ABBV's Change in Inventory at $184.0 million in Q1 2026, $25.0 million in Q4 2025, and -$2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 571.00 Mn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 143.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 31.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 145.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 143.00 Mn |
| Jun 30, 2026 | 143.00 Mn |
| Mar 31, 2026 | 184.00 Mn |
| Mar 31, 2026 | 184.00 Mn |
| Dec 31, 2025 | 25.00 Mn |
| Dec 31, 2025 | 25.00 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Sep 30, 2025 | -2.00 Mn |
| Jun 30, 2025 | 56.00 Mn |
| Jun 30, 2025 | 56.00 Mn |
| Mar 31, 2025 | 155.00 Mn |
| Mar 31, 2025 | 155.00 Mn |
| Dec 31, 2024 | 128.00 Mn |
| Dec 31, 2024 | 128.00 Mn |
| Sep 30, 2024 | 64.00 Mn |
| Sep 30, 2024 | 64.00 Mn |
| Jun 30, 2024 | 52.00 Mn |
| Jun 30, 2024 | 52.00 Mn |
| Mar 31, 2024 | 75.00 Mn |
| Mar 31, 2024 | 75.00 Mn |